Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics (NASDAQ: MGTA) is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

September 24, 2018
Magenta Therapeutics Added to Russell 2000 and 3000 Indexes

August 9, 2018
Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results

August 8, 2018
Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference

Read More News

Associated Team Members

Alexis Borisy

Stephen Sherwin, M.D.
Venture Partner